Interim analysis of COVID-19 vaccine effectiveness against
Severe Acute Respiratory Infection

V 2021

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection

BACCI, Sabrina, Nathalie NICOLAY, Ester KISSLING, Anthony NARDONE, Angie ROSE et. al.

Základní údaje

Originální název

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection

Autoři

BACCI, Sabrina (garant), Nathalie NICOLAY, Ester KISSLING, Anthony NARDONE, Angie ROSE, Marta VALENCIANO a Lenka SOUČKOVÁ (203 Česká republika, domácí)

Vydání

NA. Stockholm, 15 s. NA, 2021

Nakladatel

ECDC European Centre for Disease Prevention and Control

Další údaje

Jazyk

angličtina

Typ výsledku

Výzkumná zpráva

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Švédsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

COVID-19

Kód RIV

RIV/00216224:14110/21:00123713

Organizační jednotka

Lékařská fakulta

Klíčová slova česky

COVID-19 vakcína; efektivita; Akutní respirační infekce

Klíčová slova anglicky

COVID-19 vaccine; effectiveness; Acute Respiratory Infection

Štítky

Excelence Science, International, RIV, rivok

Příznaky

Mezinárodní význam

Změněno: 13. 1. 2022 13:16, Bc. Hana Vladíková, BBA

Anotace

V originále

This document reports the first interim pooled estimates from the ECDC study of COVID-19 vaccine effectiveness (VE), conducted through the implementation of a multi-country approach using the Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratoryconfirmed with SARS-CoV-2, version 1.0 [1].Interim pooled estimates of COVID-19 VE were calculated for all COVID-19 vaccines deployed, including the COVID-19 mRNA vaccine Comirnaty (Pfizer/BioNTech), among hospitalised individuals aged 65 years and older with SARI due to laboratory-confirmed SARS-CoV-2, across EU/EEA participating countries. The study is currently ongoing and interim analyses will be conducted on a regular basis, with results updated as relevant. Pooled estimates are from patients recruited across several hospital study sites in the EU/EEA. These interim estimates mainly cover the pre-Delta period, adding further evidence to the existing literature on COVID-19 VE during this time. While VE estimates are important to inform vaccine recommendations, it is also important to ensure that robust methods were used to produce these estimates. Hence, this document presents a detailed description of both the methods used and the characteristics of the cases and controls enrolled in the study. For more details regarding the methods of the study, reference should be made to the core ECDC protocol [1].

Návaznosti

90128, velká výzkumná infrastruktura

Název: CZECRIN III

Citovat

BACCI, Sabrina, Nathalie NICOLAY, Ester KISSLING, Anthony NARDONE, Angie ROSE, Marta VALENCIANO a Lenka SOUČKOVÁ. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection. NA. Stockholm: ECDC European Centre for Disease Prevention and Control, 2021, 15 s. NA.

@misc{1820851,
   author = {Bacci, Sabrina and Nicolay, Nathalie and Kissling, Ester and Nardone, Anthony and Rose, Angie and Valenciano, Marta and Součková, Lenka},
   address = {Stockholm},
   edition = {NA},
   keywords = {COVID-19 vaccine; effectiveness; Acute Respiratory Infection},
   language = {eng},
   location = {Stockholm},
   publisher = {ECDC European Centre for Disease Prevention and Control},
   title = {Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection},
   url = {https://www.ecdc.europa.eu/sites/default/files/documents/TRP-20211004-1860_0.pdf},
   year = {2021}
}

TY  - GEN
ID  - 1820851
AU  - Bacci, Sabrina - Nicolay, Nathalie - Kissling, Ester - Nardone, Anthony - Rose, Angie - Valenciano, Marta - Součková, Lenka
PY  - 2021
TI  - Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection
VL  - NA
PB  - ECDC European Centre for Disease Prevention and Control
CY  - Stockholm
KW  - COVID-19 vaccine
KW  - effectiveness
KW  - Acute Respiratory Infection
UR  - https://www.ecdc.europa.eu/sites/default/files/documents/TRP-20211004-1860_0.pdf
N2  - This document reports the first interim pooled estimates from the ECDC study of COVID-19 vaccine effectiveness (VE), conducted through the implementation of a multi-country approach using the Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratoryconfirmed with SARS-CoV-2, version 1.0 [1].Interim pooled estimates of COVID-19 VE were calculated for all COVID-19 vaccines deployed, including the COVID-19 mRNA vaccine Comirnaty (Pfizer/BioNTech), among hospitalised individuals aged 65 years and older with SARI due to laboratory-confirmed SARS-CoV-2, across EU/EEA participating countries. The study is currently ongoing and interim analyses will be conducted on a regular basis, with results updated as relevant. Pooled estimates are from patients recruited across several hospital study sites in the EU/EEA. These interim estimates mainly cover the pre-Delta period, adding further evidence to the existing literature on COVID-19 VE during this time. While VE estimates are important to inform vaccine recommendations, it is also important to ensure that robust methods were used to produce these estimates. Hence, this document presents a detailed description of both the methods used and the characteristics of the cases and controls enrolled in the study. For more details regarding the methods of the study, reference should be made to the core ECDC protocol [1].
ER  -

BACCI, Sabrina, Nathalie NICOLAY, Ester KISSLING, Anthony NARDONE, Angie ROSE, Marta VALENCIANO a Lenka SOUČKOVÁ. \textit{Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection}. NA. Stockholm: ECDC European Centre for Disease Prevention and Control, 2021, 15 s. NA.

Podrobný výpis o publikaci